[go: up one dir, main page]

MXPA03007319A - Anticuerpos contra egfr modificados, con inmunogenicidad reducida. - Google Patents

Anticuerpos contra egfr modificados, con inmunogenicidad reducida.

Info

Publication number
MXPA03007319A
MXPA03007319A MXPA03007319A MXPA03007319A MXPA03007319A MX PA03007319 A MXPA03007319 A MX PA03007319A MX PA03007319 A MXPA03007319 A MX PA03007319A MX PA03007319 A MXPA03007319 A MX PA03007319A MX PA03007319 A MXPA03007319 A MX PA03007319A
Authority
MX
Mexico
Prior art keywords
reduced immunogenicity
egfr antibodies
modified anti
modified
egfr
Prior art date
Application number
MXPA03007319A
Other languages
English (en)
Inventor
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA03007319A publication Critical patent/MXPA03007319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03007319A 2001-02-19 2002-02-18 Anticuerpos contra egfr modificados, con inmunogenicidad reducida. MXPA03007319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01103954 2001-02-19
PCT/EP2002/001687 WO2002066058A1 (en) 2001-02-19 2002-02-18 Modified anti-egfr antibodies with reduced immunogenicity

Publications (1)

Publication Number Publication Date
MXPA03007319A true MXPA03007319A (es) 2003-12-04

Family

ID=8176531

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007319A MXPA03007319A (es) 2001-02-19 2002-02-18 Anticuerpos contra egfr modificados, con inmunogenicidad reducida.

Country Status (14)

Country Link
US (1) US7132511B2 (es)
EP (1) EP1361893B1 (es)
JP (1) JP2004519233A (es)
KR (1) KR20030074839A (es)
CN (1) CN100488563C (es)
BR (1) BR0207283A (es)
CA (1) CA2438513C (es)
ES (1) ES2398099T3 (es)
HU (1) HUP0303173A2 (es)
MX (1) MXPA03007319A (es)
PT (1) PT1361893E (es)
RU (1) RU2297245C2 (es)
WO (1) WO2002066058A1 (es)
ZA (1) ZA200307329B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532620A (ja) * 2001-02-19 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 免疫原性の低減された人工タンパク質
ES2334494T5 (es) 2001-05-11 2013-05-29 Ludwig Institute For Cancer Research Ltd. Proteínas de unión específicas y usos de las mismas
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004032960A1 (en) * 2002-10-10 2004-04-22 Merck Patent Gmbh Pharmaceutical compositions directed to erb-b1 receptors
RS20060099A (en) 2003-08-13 2008-08-07 Pfizer Products Inc., Modified human igf-1r antibodies
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
EP2010911A4 (en) * 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS
EP2094303A1 (en) * 2006-12-22 2009-09-02 Novelix Therapeutics Gmbh Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
US20080206235A1 (en) * 2006-12-27 2008-08-28 Johns Hopkins University Compositions and methods for stimulating an immune response
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
CA2676244C (en) 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
JP5726417B2 (ja) * 2007-03-01 2015-06-03 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 組み換え抗上皮成長因子受容体抗体組成物
ES2542152T3 (es) 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
WO2009023265A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US8470314B2 (en) * 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
RU2652907C2 (ru) * 2008-06-25 2018-05-03 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Гуманизация антител кролика с использованием универсального каркаса антитела
DK2307458T3 (en) 2008-06-25 2018-07-16 Esbatech Alcon Biomed Res Unit Humanization of rabbit antibodies using a universal antibody framework
RU2567006C2 (ru) * 2008-06-25 2015-10-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Гуманизация антител кролика с использованием универсального каркаса антитела
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
EP2473521A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. B7-h4 fusion proteins and methods of use thereof
CA2777527C (en) * 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
EP3088005B1 (en) 2011-07-05 2019-01-02 biOasis Technologies Inc P97-antibody conjugates
WO2013022738A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
WO2013078271A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
JP6433424B2 (ja) 2012-07-31 2018-12-05 バイオアシス テクノロジーズ インコーポレイテッド 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
WO2014150600A2 (en) 2013-03-15 2014-09-25 Angelica Therapeutics, Inc. Modified toxins
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
MX2016003256A (es) 2013-09-12 2016-06-07 Halozyme Inc Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
CA2935195A1 (en) 2014-02-03 2015-08-06 Bioasis Technologies, Inc. P97 fusion proteins
WO2015126729A1 (en) 2014-02-19 2015-08-27 Bioasis Technologies, Inc. P97-ids fusion proteins
CN106413757B (zh) 2014-05-01 2022-01-14 比奥阿赛斯技术有限公司 p97-多核苷酸结合物
US10329348B2 (en) 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
CA3088028A1 (en) * 2018-01-11 2019-07-18 Uti Limited Partnership Treatment of fragile x syndrome
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
BR112021002622A2 (pt) 2018-08-13 2021-05-11 Beijing Percans Oncology Co. Ltd. biomarcadores para terapia de câncer
EP3902829A2 (en) 2018-12-26 2021-11-03 Innate Pharma Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
US20240145028A1 (en) * 2022-10-26 2024-05-02 Deargen Inc. Method For Data Augmentation Related To Target Protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
AU658396B2 (en) * 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
ES2278463T3 (es) * 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.

Also Published As

Publication number Publication date
CN100488563C (zh) 2009-05-20
EP1361893A1 (en) 2003-11-19
PT1361893E (pt) 2013-01-24
ZA200307329B (en) 2005-02-23
KR20030074839A (ko) 2003-09-19
ES2398099T3 (es) 2013-03-13
HUP0303173A2 (hu) 2003-12-29
WO2002066058A1 (en) 2002-08-29
EP1361893B1 (en) 2012-10-24
CN1492767A (zh) 2004-04-28
CA2438513A1 (en) 2002-08-29
US7132511B2 (en) 2006-11-07
BR0207283A (pt) 2004-08-17
RU2003127410A (ru) 2005-03-20
US20040096442A1 (en) 2004-05-20
CA2438513C (en) 2013-08-13
RU2297245C2 (ru) 2007-04-20
PL362413A1 (en) 2004-11-02
JP2004519233A (ja) 2004-07-02

Similar Documents

Publication Publication Date Title
MXPA03007319A (es) Anticuerpos contra egfr modificados, con inmunogenicidad reducida.
MXPA03007323A (es) Proteinas artificiales con inmunogenicidad reducida.
MXPA03009390A (es) Anticuerpos para integrina vla-1.
MXPA03008961A (es) Composicion de vacuna.
ZA200400521B (en) Antibodies to OPGL.
AP2004003034A0 (en) Antibodies to CD40.
EP1432444A4 (en) ANTI-BETA ANTIBODIES
ZA200208561B (en) Hydraulischer druckverstarker.
MXPA01009037A (es) I-bet.
MXPA03007915A (es) Vacuna.
MXPA03008310A (es) Interferon beta modificado con inmunogenicidad reducida.
MXPA03008706A (es) Encendedor multimodal.
MXPA03005286A (es) METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
MXPA03008164A (es) Agentes anti-epileptogenos.
AU2002349543A1 (en) Tumor antigens
MXPA03008139A (es) Fluoralcoxifenilsulfonilureas sustituidas.
MXPA03006989A (es) Leptina modificada con inmunogenicidad reducida.
MXPA03007838A (es) Interferon alfa modificado con inmunogenicidad reducida.
MXPA03007625A (es) Trombopoyetina modificada con inmunogenicidad reducida.
MXPA03008402A (es) Insulina modificada con inmunogenicidad reducida.
AU2002231806A1 (en) H. influenzae antigen basb213
MXPA01004995A (es) Bebida fermentada de aguamiel.
AU2002307943A1 (en) M. catarrhalis antigens
AU2002362494A1 (en) Tumor-peptide antigens from the human prdi-bf1-protein
MXPA03008086A (es) Protamina modificada con inmunogenicidad reducida.

Legal Events

Date Code Title Description
FG Grant or registration